Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026

Compugen (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company, will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701 at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen, June 17-19, 2026.

Rhea-AI Summary

Compugen (NASDAQ:CGEN), a clinical-stage cancer immunotherapy company, will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701 at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen, June 17-19, 2026.

The poster, presented by Dr. Oladapo Yeku on June 18, 2026, covers COM701 maintenance treatment in relapsed platinum sensitive ovarian cancer and will later be available on Compugen's website.

Argus Jun 11 session

+4.08% close to close Open Argus

Details

News Market Reaction – CGEN

In the Jun 11 session, CGEN gained 4.08%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights continued execution in Compugen’s pipeline, with a Phase 1 MAIA-ovarian...

Analysis

This announcement highlights continued execution in Compugen’s pipeline, with a Phase 1 MAIA-ovarian trial-in-progress poster for COM701 at ESMO Gynaecological Cancers 2026. It follows prior clinical updates across partnered rilvegostomig and Dato-DXd programs and the first-in-human COM503 study. Investors may monitor future MAIA-ovarian readouts, the breadth of early safety and efficacy signals, and how upcoming data might interact with the company’s financing flexibility under its $400,000,000 shelf registration.

Key Figures

Congress dates: June 17–19, 2026 Trial identifier: NCT06888921 Phase: Phase 1 +3 more

Congress dates

June 17–19, 2026

ESMO Gynaecological Cancers Congress 2026

Trial identifier

NCT06888921

MAIA-ovarian COM701 Phase 1 study

Phase

Phase 1

MAIA-ovarian COM701 maintenance trial

Poster number

170

MAIA-ovarian trial-in-progress poster

Presentation date

June 18, 2026

Poster presentation at 12:45–13:30 CEST

Presentation time

12:45–13:30 CEST

MAIA-ovarian poster session

Previous Clinical trial Reports

5 past events · Latest: Oct 17

Same Type 5 events

1. Oct 17

   Clinical data update

   24h Move

   -3.9%

   Promising ORR and DCR data for Dato-DXd plus rilvegostomig in urothelial cancer.

2. Jun 09

   Trial initiation

   24h Move

   -2.3%

   Phase 3 DESTINY-Endometrial01 initiated for ENHERTU combinations in endometrial cancer.

3. Jan 30

   Trial initiation

   24h Move

   -0.8%

   TROPION-Lung12 Phase 3 trial began for Dato-DXd plus rilvegostomig in NSCLC.

4. Jan 08

   First patient dosed

   24h Move

   -0.6%

   First patient dosed in Phase 1 trial of COM503 in advanced solid tumors.

5. Oct 30

   Multiple trials start

   24h Move

   -1.8%

   Three Phase 3 trials initiated for datopotamab deruxtecan combinations in NSCLC.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 1, trial-in-progress poster, adaptive platform clinical trial, maintenance treatment, +2 more

6 terms

phase 1 medical

"MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

trial-in-progress poster medical

"it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study"

A trial-in-progress poster is a scientific conference display that summarizes an ongoing clinical trial’s purpose, design, patient population and early observations without presenting final results. Think of it as a billboard announcing what a study is doing and how it’s being run rather than a final report. Investors watch these posters because they signal program progress, enrollment pace, safety trends and development timelines that can affect a company’s drug prospects and value.

adaptive platform clinical trial medical

"MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy"

An adaptive platform clinical trial is a flexible study design that tests multiple treatments or approaches under a single protocol and uses preplanned rules to add, drop or adjust treatment groups as results come in. Like a smart tournament bracket that reallocates resources to the most promising players, it can speed up decision-making, lower costs and reduce time to clear signals about effectiveness or safety—factors that can shorten development timelines and change an investment’s risk and value profile.

maintenance treatment medical

"to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed Platinum"

Maintenance treatment is an ongoing medical therapy given after initial successful treatment to keep a disease under control, prevent relapse, or maintain quality of life. For investors, it matters because these long-term therapies can create steady, recurring demand and predictable revenue streams for drugmakers or medical providers—like a subscription that keeps customers coming back rather than a one-time purchase.

relapsed platinum sensitive ovarian cancer medical

"Maintenance Treatment in Relapsed Platinum Sensitive Ovarian Cancer (PSOC)"

A form of ovarian cancer that has returned after initially shrinking with platinum-based chemotherapy but still responds to those platinum drugs when given again; clinicians generally call it “platinum sensitive” if the cancer comes back several months after the first treatment. For investors, this classification matters because it defines which therapies and clinical trials are appropriate, affects expected treatment success and patient numbers for new drugs, and therefore influences market size and regulatory strategy.

anti-pvrig antibody medical

"COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological"

An anti-PVRIG antibody is a laboratory-made protein designed to stick to and block PVRIG, a molecular “brake” on certain immune cells, so those cells can attack cancer more effectively. For investors, these antibodies matter because they are potential drug candidates: clinical trial results, safety, and regulatory decisions can strongly influence a developer’s prospects and share value, much like a new engine can change a car’s performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOLON, Israel, June 11, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-class anti-PVRIG antibody, at the ESMO Gynaecological Cancers Congress 2026, taking place from June 17 to June 19, 2026, in Copenhagen, Denmark.

Poster details:

Title: MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial to Evaluate Safety and Efficacy of COM701 Maintenance Treatment in Relapsed Platinum Sensitive Ovarian Cancer (PSOC)

Speaker: Dr. Oladapo Yeku, Massachusetts General Hospital, Boston, MA, U.S.

Poster presentation number: 170

Date and time of poster presentation: June 18, 2026, 12:45 - 13:30 CEST

Following the presentation, the poster will be available in the publications section of Compugen's website, www.cgen.com

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, and COM902, an anti-TIGIT antibody, have been evaluated for the treatment of solid tumors as monotherapy and in combinations. Currently, we are conducting a blinded randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between us and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that we are conducting. In addition, Compugen's has an early-stage immuno-oncology pipeline consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:

Lindsey Trickett
Head of Investor Relations and Corporate Communications
Email: lindseyt@cgen.com
Tel: +1 (628) 241-0071

 

View original content:https://www.prnewswire.com/news-releases/compugen-to-present-phase-1-maia-ovarian-trial-in-progress-poster-at-esmo-gynaecological-cancers-congress-2026-302797733.html

SOURCE Compugen Ltd.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Compugen (NASDAQ:CGEN) present at ESMO Gynaecological Cancers Congress 2026?

Compugen will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701. According to Compugen, this adaptive platform trial evaluates COM701 maintenance treatment in relapsed platinum sensitive ovarian cancer, highlighting safety and efficacy objectives for this patient population.

When is Compugen's MAIA-ovarian COM701 poster being presented at ESMO 2026?

The MAIA-ovarian COM701 poster is scheduled for June 18, 2026, from 12:45 to 13:30 CEST. According to Compugen, this presentation occurs during the ESMO Gynaecological Cancers Congress 2026 in Copenhagen, which runs from June 17 to June 19, 2026.

Who is presenting Compugen's MAIA-ovarian Phase 1 COM701 poster for CGEN?

The MAIA-ovarian Phase 1 COM701 poster will be presented by Dr. Oladapo Yeku. According to Compugen, Dr. Yeku is from Massachusetts General Hospital in Boston, U.S., and will discuss COM701 maintenance treatment in relapsed platinum sensitive ovarian cancer.

What is the focus of the MAIA-ovarian Phase 1 COM701 trial (NCT06888921)?

The MAIA-ovarian trial evaluates COM701 maintenance treatment in relapsed platinum sensitive ovarian cancer. According to Compugen, it is an adaptive platform clinical trial designed to assess the safety and efficacy of COM701, a potential first-in-class anti-PVRIG antibody, in this setting.

Where can investors access Compugen's MAIA-ovarian COM701 poster after ESMO 2026?

After the conference, the MAIA-ovarian COM701 poster will be available on Compugen's website. According to Compugen, investors and clinicians can find it in the publications section at www.cgen.com, providing ongoing access to the trial-in-progress information.

What is COM701 in Compugen's MAIA-ovarian Phase 1 study for CGEN?

COM701 is described as a potential first-in-class anti-PVRIG antibody being studied in ovarian cancer. According to Compugen, COM701 is investigated as a maintenance treatment in relapsed platinum sensitive ovarian cancer within the MAIA-ovarian adaptive platform Phase 1 trial.